IP Library Granted Patent US 7,524,814
Granted Patent B2
US 7,524,814 · App. 10/663,258 · Granted Apr 28, 2009

Lactoferrin compositions and methods of wound treatment

Assignee: Agennix, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,814
App. No.
10/663,258
Granted
Apr 28, 2009
Kind
B2
Abstract

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Claims (12)

1. A method of treating a diabetic ulcer, comprising the step of administering to a subject having a diabetic ulcer a therapeutically effective amount of a lactoferrin composition to result in an improvement or a remediation of a symptom of the diabetic ulcer.

2. The method of claim 1 , wherein said lactoferrin composition is administered topically, orally or parenterally.

3. The method of claim 2 , wherein said lactoferrin composition is administered orally.

4. The method of claim 3 further comprising administering an antacid in conjunction with said lactoferrin composition.

5. The method of claim 2 , wherein said lactoferrin composition is administered topically.

6. The method of claim 2 , wherein said lactoferrin composition is administered parenterally.

7. The method of claim 1 further comprising administering a standard wound healing therapy in combination with the lactoferrin composition.

8. The method of claim 1 , wherein the administering comprises administering said composition for at least one week to at least twelve weeks.

9. The method of claim 1 , wherein the amount of the lactoferrin that is administered is about 0.0001 μg to about 100 g per day.

10. The method of claim 1 , wherein said composition is a topical gel, a solution, capsule or a tablet having a lactoferrin concentration of about 0.0001% to about 30%.

11. The method of claim 10 , wherein said topical gel is composed from a polymer selected from the group of consisting of a vinyl polymer, polysaccharide polymer, glycosaminoglycan polymer, protein polymer, polyoxyethylene-polyoxypropylene polymer, carbomers and acrylamide polymer.

12. The method of claim 11 , wherein the polymer concentration is about 0.5% (w/w) to about 3.0% (w/w) and the polymer has a molecular weight of about 50,000 to about 13,000,000.

Assignments (2)
SECURITY AGREEMENT Recorded Mar 16, 2009
From: AGENNIX INCORPORATED
To: GPC BIOTECH AG
Reel/Frame 022399/0104 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2004
From: ENGELMAYER, JOSE; VARADHACHARY, ATUL
To: AGENNIX INCORPORATED
Reel/Frame 014963/0977 →
Continuity (2)
Provisional Application 6041098100 · Sep 16, 2002
Related Publication 20040142037A1 · Jul 22, 2004